Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319157 | 0.89 | MMP2 (0.43) | FAAHMMP13MMP2MMP14BRD4 | |
| SCHEMBL15868133 | 0.86 | BRD4 (0.43) | BRD4IL2KDM4ESMN1; SMN2 | |
| SCHEMBL15884046 | 0.86 | SCN9A (0.41) | FAAHMMP13MMP2MMP14BRD4 | |
| SCHEMBL15868129 | 0.82 | FAAH (0.47) | FAAHMMP13MMP2MMP14CA9 | |
| SCHEMBL15868143 | 0.82 | MMP2 (0.45) | FAAHMMP13MMP2MMP14 | |
| SCHEMBL15868131 | 0.80 | FAAH (0.43) | FAAHMMP13MMP2MMP14KDM4E | |
| SCHEMBL15884079 | 0.79 | BRD4 (0.40) | BRD4IL2KDM4EJMJD6 | |
| SCHEMBL15868168 | 0.79 | FAAH (0.45) | FAAHMMP13MMP2MMP14KDM4E | |
| SCHEMBL15868156 | 0.79 | FAAH (0.46) | FAAHMMP13MMP2MMP14KDM4E | |
| SCHEMBL15861810 | 0.77 | IL2 (0.54) | BRD4IL2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206136-B2 | Pyrazolyl-based carboxamides I | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206136-B2 | Pyrazolyl-based carboxamides I | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| WO-2014108337-A1 | PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS | Grünenthal GmbH (DE) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194443-A1 | Pyrazolyl-Based Carboxamides I | Grünenthal GmbH (DE) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194443-A1 | Pyrazolyl-Based Carboxamides I | AADAC, HDAC3, NLRP3 | FAAH 1038/4885MMP13 3001/4885MMP2 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.